Nevro’s AI-based spinal cord stimulator approved for chronic pain

Nevro’s Senza HFX iQ spinal cord stimulation was approved by the FDA for treating chronic back pain, the devicemaker said Oct. 13.

Advertisement

It’s the first artificial intelligence-based spinal cord stimulation system that learns from patients, according to a news release. The device will launch with algorithms aimed at treating chronic back and leg pain.

“Pain is variable from patient to patient and over time,” D. Keith Grossman, chair and CEO of Nevro, said in the release. “Using the big data from our HFX Cloud patient database, our unique HFX algorithm was developed to identify those programs where patients have been more likely to get relief in the real world.”

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.